Clinical Trial Update: A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer [Phase 2]

View source ↗

Summary

A multicenter open-label Phase II trial evaluated nivolumab plus ipilimumab as second-line therapy in elderly patients with advanced esophageal squamous cell ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: AIO-Studien-gGmbH | Conditions: Esophageal Cancer, Oesophageal Cancer | Phase 2 | Status: COMPLETED